Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials.
Ann Surg. 2021 Nov 1;274(5):713-720. doi: 10.1097/SLA.0000000000005126.
Ann Surg. 2021.
PMID: 34334656
Review.